Brand name vs Generic drugs – Are they really Equivalent?

We get asked very often about the difference between a brand name drug and a generic drug and it always centers around the question if they really Equivalent; And if so, why the big price difference? Almost everyone knows that brand name drugs are much more expensive than their generics, and the substantial price difference leads many to believe brand name drugs are more effective. Some even seem to think of generic drugs as copy-cats or knock-offs of the original brand name medication, like the so-called “Rolex” watches and “Louis Vuitton” bags sold by street vendors. However, any healthcare professionals will confirm that generic drugs are just as effective as brand-name ones. This article will provide a detailed review of why generic drugs are much cheaper but equally effective to brand name drugs. Continue reading

Combining Ambrisentan and Tadalafil provides improved treatment outcome in PAH

Combination of Ambrisentan and Tadalafil

Pharmacological agents with different mechanisms of action are often used in combination for the treatment of many health conditions. There is the proposition in medicine that combining pharmacological agents with different mechanisms generally provides superior results than increasing the dosage of a single agent. When we increase the dosage of a medication, every increment of efficacy is coupled with an increase in the risk for adverse effects. Combining agents with different mechanisms of actions can often produce the same desired therapeutic effect at lower doses of each agent. In the treatment of pulmonary hypertension, the combination associated with the best efficacy that we know today, is the combination of tadalafil and ambrisentan for patients with WHO functional class II or III pulmonary arterial hypertension (PAH). Continue reading

Ambrisentan for the treatment of pulmonary hypertension (PAH)

What is Ambrisentan?

Ambrisentan (brand named Letairis in the U.S., Volibris in the European Union and Canada) is an FDA-approved oral medication for the treatment of pulmonary hypertension. It is recommended by the FDA for patients with WHO class II and class III symptoms of pulmonary arterial hypertension (PAH) to improve exercise tolerance and slow down disease progression. The price for ambrisentan is over $10,000 per month in many countries, you can buy ambrisentan from our online pharmacy at an affordable price.

Ambrisentan is an endothelin receptor antagonist (ETA). It selectively inhibits the endothelin type-A (ETA) receptor. Endothelin-1 (ET-1) is a protein molecule our body makes for the purpose of cell to cell signaling. and ETA and ETB are receptors for ET-1 found on the smooth muscle cells of our blood vessels to mediate the effect of ET-1. When ET-1 binds with ETA  receptors, the blood vessels constrict, and blood pressure rises. When ET-1 binds with ETB receptors, the blood vessels dilate, and blood pressure drops. Continue reading

FG-3019 (Pamrevlumab) to show reversal of pulmonary fibrosis in Phase-II study

An investigational drug code named FG-3019 developed by FibroGen Inc. caught headlines recently after FibroGen published results of its recently concluded preliminary Phase-II study. The study was published in the European Respiratory Journal, in an article titled “FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in IPF.” Continue reading